Diabetic Gastroparesis Treatments (Global Market)

Diabetic gastroparesis is an incomplete gastric paralysis that leads to slower gastric emptying after eating. This complication develops against the background of chronically increased blood sugar for several years, which negatively affects the work of the human nervous system.

2015: Persistence Market Research Data

In December 2016, the analytical company Persistence Market Research published the results of a study of the global market for devices and medicines for the treatment of diabetic gastroparesis. Sales of these solutions will grow by 42% over nine years.

According to analysts, in 2015, the market for hardware and medicines for the treatment of diabetic gastroparesis reached $2.65 billion. By 2024, the figure will grow to $3.77 billion, the researchers predict.

Device for diabetic gastroparesis patient

The growth of the market in question will be facilitated by the following factors: increasing the spread of type one and two diabetes mellitus, increasing demand for minimally invasive treatments, government compensation for inpatient hospital stays in some countries, and the use of drugs to control diabetic gastroparesis symptoms such as nausea and vomiting.

The main problems for the market in Persistence Market Research are the use of over-the-counter drugs to control the symptoms of the disease, the lack of clinical evidence of the effectiveness of drugs and the termination of medical research.

Most of the global sales - about 66% - of diabetic gastroparesis treatments in 2015 came from drugs, with surgical tools taking the remaining share.

The largest manufacturers of drugs and devices for the treatment of diabetic gastroparesis are:

• Janssen Global Services;
• Salix Pharmaceuticals;
• Abbott Laboratories;
• Medtronic;
• C. R. Bard;
• Kimberly-Clark;
• Boston Scientific;
• Cardinal Health;
• Rhythm Pharmaceuticals;
• Evoke Pharma;
• Alfa Wassermann.^[1]

Notes